A Phase I, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Palovarotene in Male and Female Participants With Moderate and Severe Hepatic Impairment and Matched Participants With Normal Hepatic Function
Latest Information Update: 03 May 2025
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Pharmacokinetics
- Sponsors Ipsen
Most Recent Events
- 11 Apr 2025 New trial record